# Mechanisms of increased Alzheimer's disease pathology with R47H and R62H TREM2 variants.

- **DOI:** [10.1007/s00401-026-03036-z](https://doi.org/10.1007/s00401-026-03036-z)
- **Rating:** Limited (2.9 out of 5)
- **Verdict:** A valuable multimodal human TREM2 resource generates genotype-specific hypotheses, but small, inconsistently reported strata cannot establish the claimed epistasis or mechanisms.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-10-08
- **Evaluation page:** https://www.nabu.science/paper/10.1007%2Fs00401-026-03036-z

## Key claims

1. Epistasis between CD33 and TREM2 was demonstrated by relative normalisation of differences in β-amyloid load in TREM2var carriers of the protective CD33 allele.
   - Support: Tentative
   - Type: Primary finding
   - Basis: small stratified groups and no reported formal interaction test limit the observational epistasis inference
   - Location: Abstract; Results, Figure 1c
2. Controlling for CD33 genotype, microglial transcriptional responses to increasing β-amyloid were lower for TREM2var, particularly for R47H compared to CV.
   - Support: Tentative
   - Type: Secondary
   - Basis: unequal sample sizes, low R47H power, and unclear CV accounting confound DEG-count comparisons
   - Location: Abstract; Results, Differential transcriptomic responses; Figure 3b
3. Differential gene expression with increasing β-amyloid also suggested upregulation of β-amyloid production and binding pathways in excitatory neurons in TREM2var heterozygotes.
   - Support: Tentative
   - Type: Secondary
   - Basis: pathway associations are appropriately hedged but derive from small, unequal observational genotype groups
   - Location: Abstract; Results, Figure 5
4. They highlight mechanisms of AD risk mediated by secondary effects on astroglial and neuronal functions.
   - Support: Tentative
   - Type: Secondary
   - Basis: cross-sectional post-mortem expression associations cannot identify causal mediation of disease risk
   - Location: Abstract; Discussion, paragraphs 5–7

## Strengths

- **Rare multimodal human variant cohort** The study integrates IHC, imaging mass cytometry, snRNA-seq, and proteomics across R47H, R62H, and common TREM2 genotypes. This provides a useful human-tissue resource for comparing rare risk variants.
  - Dimension: contribution
  - Location: Methods; Results, Figures 1–5
- **Donor-aware transcriptomic modelling strategy** Nuclei are aggregated into donor-specific pseudocells, and donor identity is included as a random effect alongside pathology, genotype, region, sex, APOE4, CD33, and technical covariates.
  - Dimension: methodological rigour
  - Location: Methods, Differential gene expression analysis
- **Substantive discussion of study limits** The Discussion addresses rare-variant scarcity, subgroup imbalance, snRNA-seq sparsity, post-mortem artefacts, contralateral pathology measurement, and absent spatial or molecular plaque characterization.
  - Dimension: positioning
  - Location: Discussion, limitations paragraph

## Limitations

- **Transcriptomic sample accounting is inconsistent** The Methods call the CV snRNA-seq set 48 blocks but list 18 NDC and 21 AD blocks, while the regional AD counts sum to 30. This uncertainty bears directly on central genotype-specific transcriptomic comparisons.
  - Dimension: methodological rigour
  - Location: Methods, Single nucleus isolation for single nuclear RNA sequencing
- **Epistasis claim exceeds reported analysis** The paper calls epistasis demonstrated and strong, although the key R47H result comes from small CD33-stratified groups, Figure 1e reports trends, and no formal TREM2-by-CD33 interaction test is reported.
  - Dimension: reporting
  - Location: Abstract; Results, Figure 1c and 1e; Discussion, final paragraph
- **Power limitation is interpreted backwards** Only 34.8% of equivalent CV-associated effects were estimated detectable at the R47H sample size, yet the Discussion treats the reduced DEG count as genuine biological dampening. Low detectability cannot distinguish dampening from underpowering.
  - Dimension: positioning
  - Location: Discussion, paragraph beginning “Functional changes with TREM2 KO”

## Reliability checks

Caveats (4 of 4 checks).

- **Results check:** Noted
  - Controlling for CD33 genotype, microglial transcriptional responses to increasing β-amyloid were lower for TREM2var, particularly for R47H compared to CV: "CV (48 total: n = 18, NDC [9 MTG, 9 SOM]; n = 21, AD" (Methods, Single nucleus isolation for single nuclear RNA sequencing) vs "AD [19 MTG, 11 SOM]" (Methods, Single nucleus isolation for single nuclear RNA sequencing). The stated disease subtotals give 18 + 21 = 39 CV blocks, whereas the AD regional counts give 19 + 11 = 30 and hence 18 + 30 = the stated 48 CV blocks; this accounting correction does not change a reported expression result. → Conclusion holds
  - Minor reporting notes (1):
    - Descriptive: "Mean Braak Stage (± SD) NDC0.94 ± 0.9501 ± 0.70 AD5.08 ± 1.09*4.94 ± 1.89**5.67 ± 0.39" (Table 1, Mean Braak Stage, R47H AD column) vs "42 AD cases (Braak stage III–VI)" (Methods, Brain tissue). Using the nine R47H AD cases in Table 1, mean 4.94 and bounds 3–6, the sample SD cannot exceed sqrt[(9/8)(6−4.94)(4.94−3)] = 1.521, below the reported 1.89; fewer observed stages would not explain this because their sample size is smaller. → Conclusion holds
- **Reporting and transparency:** Noted. The Figure 1 legend labels the donor count as tissue blocks, and the methods name a paired Wilcoxon test for genotype-group comparisons without establishing the pairing or the test actually run.
  - Conflict of interest: not stated · Ethics approval: declared · Data availability: declared · Code availability: not stated
- **Reference integrity:** Clean
  - 75 references in manuscript
  - 74 of 74 checkable references found in an index
  - 1 are books, websites or datasets — counted, but not index-checkable
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
